Risk factors for PAD are wide-ranging. People who have diabetes, high blood pressure, elevated cholesterol, or atherosclerosis are among those at increased risk for the condition. Current smoking is linked to a two- to three-fold increase in risk.
PAD is caused by blockages in the leg arteries. In the early stages of the disease, it can cause pain and symptoms such as cramps in hip muscles and/or cramps in the thighs and calves after walking or climbing stairs. Other symptoms could include numbness or weakness in the legs, weak pulse in feet or legs, slow nail growth on feet, and slow hair growth on legs and feet.
In a more progressive stage of the disease, called critical limb ischemia, patients may experience constant pain even when not walking, which clinicians call “rest pain,” or have non-healing wounds and gangrene. Meanwhile, about 50% of people with PAD report having no symptoms.
The condition affects a large number of individuals and consumes a lot of resources from a health economic perspective, but it hasn’t gotten nearly the same amount of research, care innovations, and quality improvement initiatives compared to conditions like coronary artery disease or cerebrovascular disease,” says Kim G. Smolderen, PhD, MSc, associate professor of medicine (cardiology) and of psychiatry at Yale School of Medicine. “There is a lot of unawareness that is still happening not only in the general public, but also in the medical community that needs to be addressed.”
PAD is still poorly understood, but Yale researchers are at the forefront of studying not only the disease itself, but also its close connection with mental health and how social determinants may impact health outcomes. Among Yale’s leaders are Carlos Mena-Hurtado, MD, associate professor of medicine (cardiology), who with Smolderen co-directs the Vascular Medicine OutcomeS (VAMOS) research program. Through running several parallel initiatives, the team hopes to take a more holistic approach to better understanding PAD and improving patients’ quality of life.